City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field

IPO/OfferingPositive

AI Analysis

Summary

City Therapeutics, a Kendall Square-based RNAi drug developer, priced a $200M IPO and begins trading Friday as the 26th biotech IPO of 2026. The article frames the company as an 'Alnylam 2.0' amid a rebound in biotech listings.

Outcome Details

City Therapeutics priced a $200M IPO and was set to begin trading Friday; it is the 26th biotech IPO of 2026.

Importance:7/10

Sentiment:

0.50

IPORNAibiotech IPO marketKendall SquareAlnylam

Related Companies

$CTY $ALNY

Read the original article

Published by Endpoints News on October 16, 2026 10:17 AM

Read Original